Company news

Merck & Company, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

November 20, 2025

Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)

November 20, 2025

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

November 19, 2025

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

November 19, 2025

Merck Announces First-Quarter 2026 Dividend

November 18, 2025

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

November 18, 2025

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

November 14, 2025

Merck to Participate in the Jefferies Global Healthcare Conference in London

November 13, 2025

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

November 9, 2025

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

November 8, 2025

Codexis Reports Third Quarter 2025 Financial Results

November 6, 2025

Alliance for Building Better Medicine and the Virginia Innovation Partnership Celebrate $120 Million Investment from AstraZeneca, Eli Lilly, and Merck to Advance Virginia's Advanced Pharmaceutical Manufacturing Workforce

November 5, 2025

Quebec Expands Public Funding for CAPVAXIVE®

November 5, 2025

Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

November 4, 2025

Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody

November 4, 2025

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

November 3, 2025

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

October 30, 2025

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

October 29, 2025

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

October 29, 2025

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

October 28, 2025

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

October 28, 2025

U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study

October 27, 2025

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025

October 23, 2025

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer

October 23, 2025

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer

October 21, 2025

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

October 21, 2025

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

October 20, 2025

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

October 20, 2025

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

October 19, 2025

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

October 18, 2025

← Newer news releases

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 99 decks. Every deck is listed under its year.